Eyenovia, Inc.: Revolutionizing Ophthalmic Technology with Microdose Array Print Platform Eyenovia, Inc. is a promising pre-commercial ophthalmic company that has developed a revolutionary technology for the development of therapeutics. The company's proprietary microdose array print platform technology is focused on the clinical microdosing of ophthalmic pharmaceutical agents, using its branded targeted ocular delivery system, Optejet. Eyenovia, Inc. has a robust pipeline of product candidates, including MicroPine, MicroLine, and Mydcombi, all of which are in Phase III clinical development programs. MicroPine has indications for pediatric myopia progression, while MicroLine is designed to improve near vision in people with presbyopia. Mydcombi, on the other hand, has indications for pharmaceutical mydriasis. The company has partnerships with Bausch Health Ireland Limited, Arctic Vision (Hong Kong) Limited, and Senju Pharmaceutical Co., Ltd. for the development and commercialization of its products in various regions. Eyenovia, Inc. has already achieved a significant milestone by securing a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada. Headquartered in New York, Eyenovia, Inc. was formerly known as PGP Holdings V, Inc. and changed its name in May 2014. The company was incorporated in 2014 and has shown tremendous progress in revolutionizing the world of ophthalmic technology with its pioneering and innovative approach.
Eyenovia Inc's ticker is EYEN
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 11-50 employees working at Eyenovia Inc
It is eyenovia.com/pipeline/mydriasis
Eyenovia Inc is in the Healthcare sector
Eyenovia Inc is in the Biotechnology industry
The following five companies are Eyenovia Inc's industry peers: